default author photo

Paolo Pedrazzoli

University of Pavia

SCHOLARLY PAPERS

2

DOWNLOADS

89

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Primary Retroperitoneal Germ-Cell Tumours (pR-GCT): Evaluation of Treatment Outcomes of An International Collaboration (PRIMERE Study-IGG05)

Number of pages: 27 Posted: 28 Oct 2025
Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University of Cologne - University Hospital of Cologne, University of Cologne, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Comenius University, Veneto Institute of Oncology IOV - IRCCS, Veneto Institute of Oncology IOV - IRCCS, University of Groningen, University Medical Centre Groningen, Fondazione IRCCS Policlinico San Matteo, University of Pavia, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Pavia, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori and Fondazione IRCCS Istituto Nazionale dei Tumori
Downloads 50 (1,063,489)

Abstract:

Loading...

Primary Retroperitoneal Cancer, Germ Cell Tumor, Prognosis, Extragonadal Germ Cell Tumors

2.

Braf-Mutant Metastatic Non–Small-Cell Lung Cancer: Real World Data from the Italian Biomarker Atlas Database

Number of pages: 25 Posted: 12 Jun 2025
Ospedale Giovanni Paolo II, affiliation not provided to SSRN, University of Milano-Bicocca - Fondazione IRCCS San Gerardo dei Tintori, affiliation not provided to SSRN, University of Parma, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Careggi University Hospital of Florence - Clinical Oncology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), “Vito Fazzi” Hospital, University of Verona - Hospital Trust, Cardinal Massaia Hospital, Pederzoli Hospital-Peschiera del Garda, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Pisa, ASST Papa Giovanni XXIII, Regione Veneto - Azienda Ulss 3 Serenissima, affiliation not provided to SSRN, affiliation not provided to SSRN, San Giovanni di Dio Hospital,, affiliation not provided to SSRN, Università degli Studi di Genova, University of Florence, affiliation not provided to SSRN, University of Verona, affiliation not provided to SSRN, University of Pavia, Azienda Ospedaliera Ospedali Riuniti Marche Nord, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Ospedale Michele e Pietro Ferrero - Verduno, affiliation not provided to SSRN, Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Gynecologic Unit, University of Naples Federico II, University of Turin, University of Turin and affiliation not provided to SSRN
Downloads 39 (1,196,171)

Abstract:

Loading...

BRAF mutations, dabrafenib, trametinib, immunotherapy, BRAF V600E, NSCLC, real-world evidence.